NCT05407961

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

A Phase 1b, 2-Part, Investigator- and Participant-Blind, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3532226 in Participants With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 16 weeks excluding screening period for each part, respectively.

Conditions

• Diabetes Mellitus, Type 2

Interventions

Type	Name	Description
DRUG	LY3532226	Administered SC.
DRUG	Placebo	Administered SC.
DRUG	Dulaglutide	Administered SC.

Timeline

• Start date: 2022-06-07
• Primary completion: 2024-01-12
• Completion: 2024-01-12
• First posted: 2022-06-07
• Last updated: 2024-03-29

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study